Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, who have forged a ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...